Annexon

Historical price data

Annexon is a leader in developing C1q-targeting monoclonal antibodies to inhibit the classical complement pathway, a key driver of inflammation and neurodegeneration. Founded on seminal research from Stanford neurobiology, the company has built a late-stage pipeline with lead programs in Guillain-Barré Syndrome (GBS) and Geographic Atrophy (GA). Its strategy focuses on achieving functional benefits for patients by blocking complement activation upstream, potentially offering a more comprehensive and selective therapeutic profile than downstream inhibitors.

Platform of monoclonal antibodies and small molecules designed to selectively inhibit C1q, the initiator of the classical complement pathway, to comprehensively block inflammatory damage and synaptic loss.